



Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi – 110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phone: 91-11-26925858, 26925801, Fax: 91-11-26823629

E-mail: imcl@apollohospitals.com, Website : apollohospdelhi.com



Ref: IMCL/CS/BM/2024

6th February, 2024

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Re: Outcome of the Board Meeting held on 6th February, 2024

Dear Sir,

This is to inform that the Board of Directors of the Company has, at its meeting held on Tuesday, 6th February, 2024 (i.e. today), inter-alia, considered and approved the following items:

- 1. The Un-audited Financial Results of the Company for the quarter & nine months ended 31st December, 2023.**

Considered and approved the Un-audited Financial Results for the quarter and nine months ended 31st December, 2023, along with the Limited Review Report of the statutory auditor.

- 2. Appointment of Mr. Sandip Somany (DIN 00053597) as an Independent Director with effect from 1st April, 2024**


Appointed Mr. Sandip Somany (DIN 00053597) as Independent Director of the Company, for a period of 5 consecutive years effective from 1st April, 2024 to 31st March, 2029, subject to the approval of Shareholders.

The Board meeting commenced at 3.00 p.m. and ended at 5.40 p.m.

We are enclosing herewith the Un-audited Financial Results for the quarter and nine months ended 31st December, 2023, along with the Limited Review Report of the Statutory auditor - **Annexure A.**

This is for your information and record.

Thanking You,
Yours sincerely,
For Indraprastha Medical Corporation Limited


Priya Ranjan
AVP - Corporate Affairs & Legal
(Company Secretary & Compliance Officer)

Encl. as above

S.N. Dhawan & CO LLP

Chartered Accountants

2nd Floor,
51-52, Udyog Vihar Phase IV,
Gurugram-122016,
Haryana, India

Tel: +91 124 481 4444

Limited Review Report on Unaudited Quarterly and Year to Date Results

To the Board of Directors of Indraprastha Medical Corporation Limited

1. We have reviewed the accompanying statement of unaudited financial results of Indraprastha Medical Corporation Limited (“the Company”) for the quarter ended 31 December 2023 and year to date results for the period 01 April 2023 to 31 December 2023 (“the Statement”), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (“the SEBI”) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This Statement which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ (‘Ind AS 34’), prescribed under Section 133 of the Companies Act, 2013 (“the Act”) read with relevant Rules issued thereunder; and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **S. N. Dhawan & CO LLP**

Chartered Accountants

Firm Registration No.: 000050N/N500045



Rajeev K Saxena

Partner

Membership No.: 077974

UDIN No.:24077974BKEZTI6491

Place: New Delhi

Date: February 6, 2024

Statement of unaudited Financial Results for the Quarter and Nine-months ended 31st December, 2023

Amount (Rs. in crore)

S. No.	Particulars	Quarter ended			Nine-months ended		Year ended
		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.03.2023 (Audited)
1	Revenue from operations	306.46	317.00	276.93	929.97	824.62	1098.67
2	Other Income	4.27	4.17	3.08	12.00	5.24	10.03
3	Total income	310.73	321.17	280.01	941.97	829.86	1108.70
4	Expenses						
	a) Cost of material consumed	50.48	57.08	46.23	161.74	146.33	193.61
	b) Employee benefits expense	66.48	67.07	64.80	196.82	181.32	246.70
	c) Professional charges to doctors	77.05	77.59	70.15	231.67	211.23	280.55
	d) Finance cost	0.87	0.85	0.87	2.50	3.41	4.28
	e) Depreciation and amortisation expense	10.03	10.03	9.86	29.87	29.41	39.27
	f) Other expenses	65.15	64.90	58.69	194.82	168.18	227.11
	Total expenses	270.06	277.52	250.60	817.42	739.88	991.52
5	Profit before exceptional items and tax	40.67	43.65	29.41	124.55	89.98	117.18
6	Exceptional items	-	-	-	-	-	-
7	Profit before tax (PBT)	40.67	43.65	29.41	124.55	89.98	117.18
8	Tax expense						
	Current tax	11.68	11.27	9.97	33.86	27.87	31.14
	Deferred tax	(0.45)	(0.47)	(1.46)	(2.10)	(4.20)	(0.11)
9	Profit for the period after tax (PAT)	29.44	32.85	20.90	92.79	66.31	86.15
10	Other comprehensive income						
	a). (i) Items that will not be reclassified to profit or loss	1.94	(0.29)	1.30	1.19	(4.56)	(12.32)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	(0.49)	0.07	(0.32)	(0.30)	1.15	3.10
	Total other comprehensive income (Net of tax expenses)	1.45	(0.22)	0.98	0.89	(3.41)	(9.22)
11	Total comprehensive income for the period	30.89	32.63	21.88	93.68	62.90	76.93
12	Paid-up equity share capital (Face value Rs. 10/- each)	91.67	91.67	91.67	91.67	91.67	91.67
13	Reserves (excluding Revaluation Reserves) as shown in the audited balance sheet of previous year						287.78
14	Earnings per share Basic and Diluted (Rs.) - Not Annualised	3.21	3.58	2.28	10.12	7.23	9.40

Notes:

- The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 6th February, 2024.
- The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
- The Code on Social Security, 2020 has been enacted, which could impact the contributions by the company towards Provident Fund and Gratuity. The effective date from which the changes are applicable is yet to be notified. Impact if any, of the change will be assessed and accounted in period of notification of relevant provisions.
- Previous year/period figures have been regrouped / rearranged wherever necessary.

Place : New Delhi
Date : 6th February, 2024



Shivakumar Pattabhiraman
(Managing Director)
DIN: 08570283